Who are Sedation by ketamine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, Midazolam+Ketamine Combination, Magnesium Sulfate, Heptahydrate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sedation-by-ketamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sedation by ketamine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sedation by ketamine (Sedation by ketamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anesthetic. Area: Anesthesiology.

phase 3 Anesthetic NMDA receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Sedation by ketamine (Sedation by ketamine) — University Hospital, Montpellier. Ketamine acts as an NMDA receptor antagonist, blocking the action of glutamate at the NMDA receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sedation by ketamine TARGET	Sedation by ketamine	University Hospital, Montpellier	phase 3	Anesthetic	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Midazolam+Ketamine Combination	Midazolam+Ketamine Combination	Universidad de Cartagena	marketed	Sedative-hypnotic and dissociative anesthetic combination	GABA-A receptor (midazolam); NMDA receptor (ketamine)
Magnesium Sulfate, Heptahydrate	Magnesium Sulfate, Heptahydrate	University of Utah	marketed	Electrolyte supplement / anticonvulsant / bronchodilator	NMDA receptor, voltage-gated calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anesthetic class)

Express Specialty Pharmacy · 1 drug in this class
Nantes University Hospital · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class
Universidad de Colima · 1 drug in this class
University Hospital, Montpellier · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sedation by ketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/sedation-by-ketamine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing